Study on Combining Chemotherapy and Immunotherapy with Yittrium-90 for Better Tumor Control

Inclusion Criteria

• Adults aged 18 and older.
• Diagnosed with a specific type of liver cancer (iCCA) that has not been treated before, or if treated, it was more than 6 months ago.
• Cancer that cannot be surgically removed safely.
• Tumors that can be measured and are at least 2 cm in size.
• Good overall health with a performance status score of 0 or 1.
• No liver cirrhosis or signs of it on imaging tests.
• No cancer outside the liver, except for nearby lymph nodes that can be removed during surgery.
• Good organ function based on lab tests.
• Able to complete all required tests and procedures in the study.
• Willing to give consent to participate in the study.

Exclusion Criteria

• Women who are pregnant or breastfeeding.
• History of organ transplant.
• Active or past autoimmune diseases or immune deficiencies, with some exceptions like controlled thyroid or diabetes conditions.
• Recent use of immunosuppressive medications, with some exceptions for low-dose or specific types of steroids.
• Certain liver conditions or other types of cancer like gallbladder or pancreatic cancer.
• Blood clots in major liver veins.
• Previous treatments for iCCA, except for specific allowed therapies.
• Allergies to study drugs.
• Active hepatitis B or C without treatment.
• Certain conditions found during angiography that prevent safe treatment.
• Large tumor burden in the liver.
• Inability to protect non-target areas during treatment.
• Low serum albumin or high liver enzyme levels.
• Other serious illnesses or conditions that pose additional risks.
• Poor compliance or inability to follow study procedures.
• Prisoners or those involuntarily incarcerated.
• Cognitive impairments affecting decision-making.
• Participation in another clinical trial.